March 2, 2020 10:03 AM ESTUpdated March 3, 04:29 AM
R&D

Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

Amber Tong

Clas­si­cal Hodgkin lym­phoma was the first blood can­cer that Mer­ck’s Keytru­da was ap­proved to treat. Three years af­ter that OK ar­rived — kick­ing off a spate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times